Cargando…
Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11)-induced growth inhibition
[Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11) (SP-G) is a novel anticancer agent that has recently completed phase I clinical trials. SP-G inhibits mitogenic neuropeptide signal transduction and small cell lung cancer (SCLC) cell growth in vitro and in vivo. Using the SCLC cell line series GLC1...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377129/ https://www.ncbi.nlm.nih.gov/pubmed/12771999 http://dx.doi.org/10.1038/sj.bjc.6600957 |